

Press Release



**Inamed GmbH
Headquarters & Logistics**

Wohraer Str. 37
D – 35285 Gemünden
Tel. +49 (0)6453 64818-0
Fax +49 (0)6453 64818-22
www.inamed.de

Pages: 3

Date: November 14, 2003

INAMED LICENCES AKITA INHALATION DEVICE TO BAYER HEALTHCARE AG, BIOLOGICAL PRODUCTS

Exclusive deal with Inamed will allow Bayer to offer most technologically advanced inhalation dosing of aerosolized alpha-1 antitrypsin protein

Gemünden/Wohra, Germany – Inamed GmbH announced today the signing of a deal with Bayer HealthCare AG, Biological Products (North Carolina, USA) for exclusive use of its new advanced inhalation technology for the dosing of alpha-1 antitrypsin (AAT) protein. This deal includes Inamed's new model of the AKITA, an inhalation device based on a computer-controlled inhalation system. This deal and the cooperation with Bayer HealthCare AG is an important step for Inamed regarding to the further development of the AKITA inhalation system for dose-critical drugs.

The new version of the AKITA device provides the most advanced technology, offering significant advantages in medical and patient convenience for inhaling aerosolized AAT. The new AKITA is small and lightweight; highly efficient, resulting in less wasted product; delivers individualized and reproducible dosing tailored to each patient through smart card technology; and requires less time to inhale the prescribed dose. Under the terms of the deal, Bayer HealthCare AG will have worldwide exclusive rights (for inhaled AAT) to the new AKITA device and any other products developed by Inamed based on the same technology for clinical development and marketing of its inhaled AAT products. Currently, all commercially available AAT products must be administered intravenously.

Dr. Gerhard Scheuch, CEO of Inamed, said, "We are extremely excited to be working with Bayer HealthCare AG in the development of AAT as an aerosol. We are pleased that Bayer HealthCare AG recognizes the important advances represented by the AKITA system and will be using it to provide important benefits to their patients. This is an important milestone in our business development strategy, to license the AKITA technology exclusively for certain indications."

Bernhard Schaefer, vice president of global strategic marketing for Bayer HealthCare AG commented on the importance of the deal with Inamed. "The AKITA technology represents a major advance in inhalation dosing. While we are excited about the opportunities this deal offers Bayer HealthCare AG for developing our an aerosolized AAT product, we are most pleased about the tremendous improvements in efficiency and patient convenience the device offers."

About Bayer HealthCare AG

Bayer HealthCare AG combines the global activities of the divisions of Bayer AG in the fields of Biological Products, Consumer Care, Diagnostics, Animal Health, and Pharmaceuticals. More than 34,000 employees support the worldwide operations of Bayer HealthCare.

Bayer Biological Products is part of the worldwide operations of Bayer HealthCare AG, a subgroup of Bayer AG. Bayer HealthCare AG is one of the world's leading innovators in the health care and medical products industries.

Information about Bayer HealthCare AG, Biological Products Division can be found at www.bayerbiologicals.com.

About Inamed

Inamed GmbH, Intelligent Aerosol Medicine, is a Germany-based drug delivery company, specializing in aerosol technology and inhalation systems. Inamed develops and markets highly efficient inhalers that allow dosing flexibility by controlling the patient's breathing pattern, thus, leveraging the full benefit of aerosolized drug applications. With the innovative AKITA inhalation system, the inhalation treatment can be tailored individually to each patient through smart card technology to achieve a reproducible dosage in the human lungs.

Inamed, as a leading service provider for in-vitro and in-vivo inhalation studies, partners globally with leading pharmaceutical and biotechnology companies to apply their inhalation platforms to pharmaceuticals that require critical dosage control.

Inamed GmbH, Intelligent Aerosol Medicine, is privately held and has facilities in Munich (R&D) and Gemünden/Wohra (Headquarters and Logistics). www.inamed.de

Inamed is advised by MedVenture Partners, Munich on the licensing strategy

Contacts

Inamed GmbH

Axel Fischer
Tel: +49 6453 64 81 824
Fax: +49 6453 64 81 822
E-Mail: fischer@inamed.de

Bayer HealthCare AG, Biological Products

Tricia McKernan
Tel.: +1 919.316.6316
Fax: +1 919.316.6316
E-Mail: tricia.mckernan.b@bayer.com

Steve Walker
Tel.: +1 816.512.2270
Fax: +1 816.474.7783
E-Mail: walkers@fleishman.com

Helmut Schäfers
Tel. +49 214 – 30 58308
helmut.schaefers.hs@bayer-ag.de

Gemünden, November 14, 2003